A Patch for Schizophrenia
The US Food and Drug Administration (FDA) has approved a first-of-its-kind patch for schizophrenia.
First Digital Medication Approved
Abilify MyCite is the first digital medication system approved by the US Food and Drug Administration (FDA).
First Tardive Dyskinesia Rx Approved
The US Food and Drug Administration (FDA) has approved the first drug to treat tardive dyskinesia.
Schizophrenia Rx Now Approved for Teens
The US Food and Drug Administration (FDA) has approved a new treatment for teens with schizophrenia.
A New Warning for Olanzapine
The US Food and Drug Administration (FDA) is warning about the possibility for a rare but serious skin reaction from a particular antipsychotic.
New Warning For Aripiprazole
The US Food and Drug Administration (FDA) is warning about possible impulse-control problems, such as compulsive or uncontrollable urges, tied to a particular antipsychotic.
Spotting the Treatment Gap in Diabetes Screening
Patients with severe mental illness face an increased risk for diabetes. And new evidence suggests there may be room for improvement when it comes to screening these patients for the condition.
A Shot for Schizophrenia
After a new FDA approval, patients who face schizophrenia every day may not have to take their medication every day to stay healthy.
Mental Health Rx Gets Go-Ahead
A newly approved medication could help some patients with serious mental health disorders.
Schizophrenia, Bipolar Disorder Rx Approved
DUBLIN and BUDAPEST, Hungary, Sept. 17, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN) and Gedeon Richter Plc. announced today that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR™ (cariprazine) capsules, an atypical antipsychotic, for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for treatment of schizophrenia in adults.